Efficacy and Safety of Switching From Oral Bisoprolol to Transdermal Patch in Japanese Patients With Chronic Heart Failure-Reference-Cited by-同舟云学术

Efficacy and Safety of Switching From Oral Bisoprolol to Transdermal Patch in Japanese Patients With Chronic Heart Failure

Published:2018 Issue:1 Volume:82 Page:141-147
ISSN:1346-9843
Container-title:Circulation Journal
language:en
Short-container-title:Circ J

Author:

Momomura Shin-ichi¹,Saito Yoshihiko²,Yasumura Yoshio³,Yamamoto Kazuhiro⁴,Sakata Yasushi⁵,Daimon Masao⁶,Kinugawa Koichiro⁷,Okamoto Hiroshi⁸,Dohi Naoki⁹,Komuro Issei¹⁰

Affiliation:

1. Division of Cardiovascular Medicine, Saitama Medical Center, Jichi Medical University

2. First Department of Internal Medicine, Nara Medical University

3. Department of Cardiology, Amagasaki Chuo Hospital

4. Division of Cardiovascular Medicine, Department of Molecular Medicine and Therapeutics, Tottori University

5. Department of Cardiovascular Medicine, Osaka University

6. Department of Clinical Laboratory, The University of Tokyo

7. Second Department of Internal Medicine, University of Toyama

8. Department of Cardiovascular Medicine, Hokkaido University

9. Research and Development Department, Toa Eiyo

10. Department of Cardiovascular Medicine, The University of Tokyo

Publisher

Japanese Circulation Society

Subject

Cardiology and Cardiovascular Medicine,General Medicine

Link

https://www.jstage.jst.go.jp/article/circj/82/1/82_CJ-17-0532/_pdf

Reference10 articles.

1. 1. Matsuoka H, Kuwajima I, Shimada K, Mitamura H, Saruta T. Comparison of efficacy and safety between bisoprolol transdermal patch (TY-0201) and bisoprolol fumarate oral formulation in Japanese patients with grade I or II essential hypertension: Randomized, double-blind, placebo-controlled study. J Clin Hypertens (Greenwich) 2013; 15: 806–814.

2. 2. Matsuoka H, Kuwajima I, Shimada K, Mitamura H, Saruta T. A placebo-controlled, randomized, double-blind, dose-finding study of 2 mg, 4 mg and 8 mg bisoprolol transdermal patches (TY-0201) in Japanese patients with grade I-II essential hypertension. Prog Med 2013; 33: 2413–2420.

3. 3. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: An update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 2015; 28: 1–39.

4. 4. Rector TS, Cohn JN. Assessment of patient outcome with the Minnesota Living with Heart Failure questionnaire: Reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan. Am Heart J 1992; 124: 1017–1025.

5. 5. Guyatt GH. Measurement of health-related quality of life in heart failure. J Am Coll Cardiol 1993; 22(Suppl A): 185A–191A.

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Comparative Study to Investigate the Effects of Bisoprolol in Patients with Chronic Heart Failure and Hypertension When Switched from Tablets to Transdermal Patches;Journal of Personalized Medicine;2023-05-01

2. Preventative effects of bisoprolol transdermal patches on postoperative atrial fibrillation in high-risk patients undergoing non-cardiac surgery: A subanalysis of the MAMACARI study;Journal of Cardiology;2021-11

3. Comparison of the Transdermal Bisoprolol Patch with Oral Bisoprolol Fumarate Administration as a Therapeutic Agent for Idiopathic Frequent Premature Ventricular Contractions;International Heart Journal;2020-05-30

4. Pilot study of bisoprolol 8 mg transdermal patch at bedtime before coronary computed tomography angiography;Journal of Cardiology;2020-04

5. Effects of Bisoprolol Transdermal Patches for Prevention of Perioperative Myocardial Injury in High-Risk Patients Undergoing Non-Cardiac Surgery　― Multicenter Randomized Controlled Study ―;Circulation Journal;2020-03-25